SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iterum Therapeutics plc (ITRM)PRNewsWire • 07/07/21
Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative BuySeeking Alpha • 07/05/21
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021GlobeNewsWire • 05/07/21
Iterum Therapeutics: Delayed Review Of Its NDA For Sulopenem, But Upside Still ExistsSeeking Alpha • 04/29/21